Recommendation ID

Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent but potentially serious adverse events:

Any explanatory notes
(if applicable)

1.2Clinicians wishing to use a swallowable gastric balloon capsule for weight loss should:

  • Inform the clinical governance leads in their healthcare organisation.

  • Give patients (and their families and carers as appropriate) clear written information to support shared decision making, including NICE's information for the public.

  • Ensure that patients (and their families and carers as appropriate) understand the procedure's safety and efficacy, and any uncertainties about these.

  • Audit and review clinical outcomes of all patients having the procedure. The main efficacy and safety outcomes identified in this guidance can be entered into NICE's interventional procedure outcomes audit tool (for use at local discretion).

  • Discuss the outcomes of the procedure during their annual appraisal to reflect, learn and improve.

1.3Further research could be in the form of randomised controlled trials comparing the procedure with current standard therapies, or an observational cohort study, including using registry data. Studies should include details of patient selection such as body mass index and other treatments such as diet and lifestyle changes. They should also report:

  • short- and long-term weight loss

  • quality of life

  • metabolic parameters

  • the need for later surgery.

Source guidance details

Comes from guidance
Swallowable gastric balloon capsule for weight loss
Date issued
November 2020

Other details

Is this a recommendation for the use of a technology only in the context of research? Yes  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 18/11/2020